All In Biotech

Drug Trial Radar · NCT05822908

A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD

A Phase 1/2a, Open-label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered VO659 in Participants With Spinocerebellar Ataxia Types 1, 3 and Huntington's Disease

Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

68

Planned (sponsor's estimate)

Start

Feb 14, 2023

Primary completion

Apr 1, 2028

Study completion Oct 15, 2028

Sponsor

Lead sponsor
Vico Therapeutics B. V.Industry
Sponsor type
Industry
First posted
Apr 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 25 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this first-in-human clinical trial is to assess the safety and tolerability of four doses of a new study drug called VO659 in people with genetic disorders called spinocerebellar ataxia type 1, type 3 or Huntington's disease. Another aim is to determine the concentrations of the study drug in the cerebral spinal fluid and blood after single and multiple doses. Study drug will be administered by lumbar intrathecal bolus injections.

Conditions

  • Spinocerebellar Ataxia Type 1
  • Spinocerebellar Ataxia Type 3
  • Huntington Disease

Interventions

  • VO659Drug

    VO659 is an antisense oligonucleotide targeting CAG repeats in mRNA transcripts

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence & dose relationships of treatment-related AEs, SAEs, AEs of special interest (AESI), severe events (NCI- CTCAE Grade 3 or higher).Time frame: Day 0-253
  2. Vital signsTime frame: Day 0-253
  3. Body weightTime frame: Day 0-253
  4. Electrocardiogram (ECG) RR intervalTime frame: Day 0-253
  5. Electrocardiogram (ECG) - PR intervalTime frame: Day 0-253
  6. Electrocardiogram (ECG) - QTc intervalTime frame: Day 0-253
  7. Laboratory safety parameters in blood - white blood cell countTime frame: Day 0-253
  8. Laboratory safety parameters in blood - hemoglobinTime frame: Day 0-253
  9. Laboratory safety parameters in blood - plateletsTime frame: Day 0-253
  10. Laboratory safety parameters in blood - prothrombin time (PT)Time frame: Day 0-253
  11. Laboratory safety parameters in blood - activated partial thromboplastin clotting time (aPTT)Time frame: Day 0-253
  12. Laboratory safety parameters in blood - international normalised ratio (INR)Time frame: Day 0-253
  13. Laboratory safety parameters in blood - blood urea nitrogenTime frame: Day 0-253
  14. Laboratory safety parameters in blood - carbon dioxideTime frame: Day 0-253
  15. Laboratory safety parameters in blood - creatinineTime frame: Day 0-253
  16. Laboratory safety parameters in blood - glucoseTime frame: Day 0-253
  17. Laboratory safety parameters in blood - chlorideTime frame: Day 0-253
  18. Laboratory safety parameters in blood - potassiumTime frame: Day 0-253
  19. Laboratory safety parameters in blood - sodiumTime frame: Day 0-253
  20. white blood cell (WBC) count in cerebrospinal fluid (CSF)Time frame: Day 0-253
  21. Protein levels in cerebrospinal fluid (CSF)Time frame: Day 0-253
  22. Structural imaging assessment of any new abnormalitiesTime frame: Day 0-253
  23. Percentage of participants with suicidal ideation or behaviour, as assessed by the Columbia suicide severity rating scale (C-SSRS).Time frame: Day 0-253

Locations

14 sites in 6 countries. Site status is shown where the registry gives one.

  • Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • Centre Hospitalier Universitaire dÁngers

    Angers, France · Recruiting

  • CHU Gui de Chauliac Montpellier- Expert Center of Neurogenetic diseases, Department of Neurology

    Montpellier, France · Recruiting

  • Universtiry Hospitals Pitie Salpetriere - Charles foix - Paris

    Paris, France · Recruiting

  • Katholisches Klinikum Bochum

    Bochum, Germany · Recruiting

  • Deutsches Zentrum fur Neurodegenerative Erkrankungen (DZNE)

    Bonn, Germany · Recruiting

  • Universitatsklinikum Essen - Neurologie

    Essen, Germany · Recruiting

  • Universitatsklinikum Tübingen

    Tübingen, Germany · Recruiting

  • Meir Medical Center

    Kfar Saba, Israel · Recruiting

  • Sourmansky Medical Center

    Tel Aviv, Israel · Recruiting

  • Leiden University Medical Center LUMC

    Leiden, Netherlands · Active not recruiting

  • Radbout University Medical Centre

    Nijmegen, Netherlands · Active not recruiting

  • University College London Hospitals NHS Foundation

    London, United Kingdom · Recruiting

  • John Radcliffe Hospital

    Oxford, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.